Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Global Health, Boston University School of Public Health, Boston, MA, USA.
Trop Med Int Health. 2018 Feb;23(2):206-220. doi: 10.1111/tmi.13013. Epub 2018 Jan 10.
To assess the relationship between CD4 count at presentation and ART uptake and assess predictors of timely treatment initiation in rural KwaZulu-Natal, South Africa.
We used Kaplan-Meier and Cox proportional hazards models to assess the association between first CD4 count and time from first CD4 to ART initiation among all adults presenting to the Hlabisa HIV Treatment and Care Programme between August 2011 and December 2012 with treatment-eligible CD4 counts (≤ 350 cells/mm ). For a subset of healthier patients (200 < CD4 ≤ 350 cells) residing within the population surveillance of the Africa Health Research Institute, we assessed sociodemographic, economic and geographic predictors hypothesised to influence ART uptake.
A total of 4739 patients presented for care with eligible CD4 counts. The proportion initiating ART within six months of diagnosis was 67% (95% CI 63, 71) in patients with CD4 ≤ 50, 59% (0.55, 0.63) in patients with CD4 151-200 and 48% (95% CI 44, 51) in patients with CD4 301-350. The hazard of starting ART fell by 17% (95% CI 14, 20) for every 100-cell increase in baseline CD4 count. Among healthier patients under demographic surveillance (n = 193), observable sociodemographic, economic and geographic predictors did not add discriminatory power beyond CD4 count, age and sex to identify patients at high risk of non-initiation.
Individuals presenting for HIV care at higher CD4 counts were less likely to initiate ART than patients presenting at low CD4 counts. Overall, ART uptake was low. Under new guidelines that establish ART eligibility regardless of CD4 count, patients with high CD4 counts may require additional interventions to encourage treatment initiation.
评估初次 CD4 计数与开始 ART 治疗之间的关系,并评估南非夸祖鲁-纳塔尔省农村地区及时开始治疗的预测因素。
我们使用 Kaplan-Meier 和 Cox 比例风险模型来评估所有在 2011 年 8 月至 2012 年 12 月期间到 Hlabisa HIV 治疗和护理计划就诊且 CD4 计数(≤350 个细胞/mm)符合治疗条件的成年人中,首次 CD4 计数与首次 CD4 计数至开始 ART 治疗之间的时间关系。对于居住在非洲健康研究所人群监测范围内的一组健康状况较好的患者(200<CD4<350 个细胞),我们评估了假设影响 ART 接受率的社会人口统计学、经济和地理预测因素。
共有 4739 名患者因符合条件的 CD4 计数就诊。在 CD4<50 的患者中,有 67%(95%CI 63,71)在诊断后 6 个月内开始接受 ART,在 CD4 为 151-200 的患者中,有 59%(0.55,0.63)开始接受 ART,在 CD4 为 301-350 的患者中,有 48%(95%CI 44,51)开始接受 ART。基线 CD4 计数每增加 100 个细胞,开始接受 ART 的风险就会降低 17%(95%CI 14,20)。在接受人口监测的健康状况较好的患者中(n=193),除了 CD4 计数、年龄和性别外,可观察到的社会人口统计学、经济和地理预测因素并没有增加识别高风险未开始治疗患者的区分能力。
与 CD4 计数较低的患者相比,CD4 计数较高的患者开始接受 ART 的可能性较低。总体而言,ART 接受率较低。在新的指南下,无论 CD4 计数如何,都可以开始接受 ART,这可能需要对高 CD4 计数的患者进行额外的干预措施,以鼓励他们开始治疗。